Skip to main content
SpringerLink
Log in

Im Fokus: Das hepatozelluläre Karzinom

Die wichtigsten Studienergebnisse der vergangenen Monate auf einen Blick

In focus: hepatocellular carcinoma

The most important study results of the past months at a glance

  • Update Onkologie
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. RKI. https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Leberkrebs/leberkrebs_node.html (abgerufen am 15. Febr. 2019)

  2. Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. https://www.awmf.org/uploads/tx_szleitlinien/032-053OLl_S3_Hepatozellul%C3%A4res_Karzinom_Diagnostik_Therapie_2013-abgelaufen.pdf ; (abgerufen am 15. Febr. 2019)

  3. Forner A et al (2018) Hepatocellular carcinoma. Lancet 391(10127):1301–1314

    Article  Google Scholar 

  4. Rajyaguru DJ et al (2018) Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol 36(6):600–608

    Article  CAS  Google Scholar 

  5. Yoon SM et al.(2018) Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol.4(5):661–669

    Article  Google Scholar 

  6. Kudo M et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173

    Article  CAS  Google Scholar 

  7. Abou-Alfa GK et al (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379(1):54–63

    Article  CAS  Google Scholar 

  8. Zhu AX et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α‑fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282–296

    Article  CAS  Google Scholar 

  9. Melero I et al (2017) Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The checkmate 040 study. J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.4_suppl.226

    Article  Google Scholar 

  10. Zhu AX et al (2018) KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940–952

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäres Krebszentrum Leipzig (UCCL), Universitätsklinikum Leipzig, Liebigstraße 22, 04103, Leipzig, Deutschland

    F. Lordick

Authors
  1. F. Lordick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Lordick.

Additional information

Die Beiträge stammen aus dem Handbuch ONKOLOGIE 2019 und entsprechen in Auszügen den Seminarunterlagen des 14. Onkologie-Update-Seminars 2019 der med-update GmbH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lordick, F. Im Fokus: Das hepatozelluläre Karzinom. best practice onkologie 14, 180–184 (2019). https://doi.org/10.1007/s11654-019-0138-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-019-0138-6

Search

Navigation